Edition:
United States

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

5.78USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.78
Open
$5.77
Day's High
$5.87
Day's Low
$5.76
Volume
22,741
Avg. Vol
70,666
52-wk High
$15.00
52-wk Low
$5.25

Latest Key Developments (Source: Significant Developments)

Uniqure Q4 loss per share $0.58
Wednesday, 15 Mar 2017 07:00am EDT 

Uniqure Nv : Uniqure announces 2016 financial results and provides update on company progress . Q4 loss per share $0.58 . Uniqure nv- as of december 31, 2016, company held cash and cash equivalents of $132.5 million, compared with $221.6 million as of december 31, 2015 . Uniqure nv- company expects its cash on hand will be sufficient to fund operations into 2019 . Uniqure nv says plans to advance hemophilia b program into late-stage clinical development are ongoing, with a pivotal trial expected to begin in 2018 . Uniqure nv says continues to advance amt-130 towards filing an investigational new drug (ind) application to begin clinical studies in 2018 .Uniqure nv -intends to reduce capital expenditures in 2017 and 2018 and realize operational cost savings from strategic restructuring initiated in nov 2016.  Full Article

Uniqure reports Q3 loss per share EUR 0.54
Tuesday, 22 Nov 2016 07:05am EST 

Uniqure Nv : Uniqure Nv - strategic review completed . Says cutting workforce by 20 to 25 percent by end of 2017 . Uniqure Nv - Uniqure expects to realize EUR 5 million to EUR 6 million of annualized cost savings by end of 2017 . Uniqure Nv - Uniqure believes its existing cash resources will be sufficient to fund operations into 2019 . Uniqure Nv - expects to realize €5 million to €6 million of annualized cost savings in personnel and other related operating expenses . Says cutting workforce by 20 to 25 percent by end of 2017 . Uniqure Nv says expects to further reduce planned operating expenses by EUR 11 million to EUR 15 million over next two years through focusing of its pipelin . Uniqure-Regarding product candidates in sanfilippo b,parkinsons' disease, co initiated talks with its collaborators to explore options for the programs . Uniqure Nv - discussions with its collaborators including their potential transfer or partnership . Uniqure Nv - will restructure its research and development organization in netherlands and consolidate manufacturing in united states . In early 2017 co will commence scaled-up production of clinical material in its lexington, MA manufacturing facility . Uniqure announces financial results for third quarter 2016 and provides update on company progress . Q3 revenue eur 6.5 million versus eur 3.1 million . Q3 earnings per share view EUR -0.80 -- Thomson Reuters I/B/E/S . Q3 loss per share EUR 0.54.  Full Article

Uniqure completes strategic review to refocus its pipeline and reduce operating costs
Tuesday, 15 Nov 2016 07:05am EST 

Uniqure Nv : Preparation underway for late-stage development in Hemophilia B . Uniqure sees elimination of approximately 50 to 60 positions, or 20 pctto 25 pct of global headcount, by end of 2017 . Uniqure expects to further reduce planned operating expenses by eur 11 to eur 15 million over next two years . Uniqure expects to realize eur 5 to eur 6 million of annualized cost savings in personnel and other related operating expenses . Will pursue partnering opportunities for its academic-sponsored program in parkinson's disease . Previous organizational structure based on therapeutic areas of focus is being eliminated . Cost savings from actions expected to extend cash resources into 2019 . Manufacturing to be consolidated into lexington, ma . Will restructure its research and development organization in Netherlands and consolidate manufacturing in United States . Initiated discussions with its collaborator regarding potential discontinuation of licensing discussions for AMT-110 .Uniqure completes strategic review to refocus its pipeline, reduce operating costs and deliver long-term shareholder value.  Full Article

Uniqure posts Q2 loss per share of EUR 0.77
Thursday, 25 Aug 2016 04:18pm EDT 

Uniqure NV : Uniqure announces financial results for second quarter 2016 and update on company progress . Q2 loss per share EUR 0.77 . Q2 earnings per share view EUR -0.78 -- Thomson Reuters I/B/E/S . Uniqure says data from Sanfilippo B And Parkinson's disease studies expected in Q1 2017 .Uniqure says additional data on AMT-060 in Hemophilia B expected later this year.  Full Article

Uniqure Q2 loss per share eur 0.77
Thursday, 25 Aug 2016 04:05pm EDT 

Uniqure Nv : Uniqure announces financial results for second quarter 2016 and update on company progress . Q2 loss per share eur 0.77 .Q2 earnings per share view eur -0.78 -- Thomson Reuters I/B/E/S.  Full Article

Uniqure Q1 loss per share EUR0.83
Tuesday, 31 May 2016 05:00am EDT 

Uniqure NV : Uniqure announces results for first quarter 2016 . Q1 earnings per share view EUR -0.73 -- Thomson Reuters I/B/E/S . Q1 loss per share EUR 0.83 . On May 6, executed a second amended and restated loan agreement with Hercules Technology Growth Capital, Inc . Maturity date of loan facility was also extended from June 30, 2017 to March 1, 2020 .Loan agreement includes a total commitment from Hercules of up to $40 million, of which $20 million is currently outstanding.  Full Article

Uniqure NV Announces preliminary topline results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
Thursday, 7 Jan 2016 06:00am EST 

Uniqure NV:Announces preliminary topline results from low-dose cohort in hemophilia b phase i/ii gene therapy clinical trial.Says four of five patients have fully discontinued prophylactic recombinant factor IX therapy.Says early data from the low-dose cohort suggest that amt-060 is generally well-tolerated.  Full Article

Uniqure NV appoints Dan Soland as Chief Executive Officer
Friday, 18 Dec 2015 06:30am EST 

Uniqure NV:Announced the appointment of Dan Soland as the new Chief Executive Officer of the Company.Soland will succeed Jörn Aldag, who has decided to step down as CEO, a role he has held since 2009.Soland will also be nominated for appointment to uniQure's Management Board.Aldag will be available to assist the Company during the transition.  Full Article

Uniqure NV announces receipt of $53 mln from Bristol-Myers Squibb
Monday, 10 Aug 2015 05:03am EDT 

Uniqure NV:Says receipt of an additional $53 mln from Bristol-Myers Squibb in accordance with companies' strategic collaboration.To develop gene therapies to treat range of cardiovascular diseases.Bristol-Myers Squibb selected three new collaboration targets triggering a $15 mln cash payment to uniQure.  Full Article

Uniqure NV announces closing of follow on public offering
Wednesday, 15 Apr 2015 01:00pm EDT 

Uniqure NV:Announced the closing of its previously announced follow on public offering of 3,000,000 ordinary shares at an offering price of $29.50 per ordinary share.In addition, uniQure has granted the underwriters a 30-day option to purchase up to an additional 450,000 ordinary shares from uniQure at the offering price, less underwriting discounts.Leerink Partners LLC, Cowen and Company, LLC, and Piper Jaffray & Co. acted as the joint book-running managers for the offering.Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC, acted as co-managers.  Full Article

More From Around the Web

BRIEF-Uniqure files for mixed shelf of $250 mln

* Uniqure NV files for mixed shelf of $250 million - SEC filing Source text: (http://bit.ly/2mNxrZc) Further company coverage: